Overview of advances in acute stroke treatment, focusing on the OPTION trial—an investigation led by Junwei Hao and Ran MO, addressing intravenous tenecteplase for non-large vessel occlusion stroke in the extended window.

Audio overview, where we'll be discussing the key findings from the late-breaking OCEANIC-STROKE phase 3 trial, presented by Dr. Sharma. This was a pivotal study focusing on the risks and benefits of asundexian, a factor XIa inhibitor, in acute non-cardioembolic ischemic stroke and high-risk transient ischemic attack (TIA).

Intravenous tenecteplase plus endovascular thrombectomy showed acceptable safety but no significant improvement in functional outcomes for basilar artery occlusion patients presenting within 4.5-24 hours after stroke onset.

The objective of this trial is to evaluate the safety and effectiveness of Onyx LES embolization of the middle meningeal artery (MMA) for symptomatic subacute and chronic subdural hematoma.

Branch atheromatous disease (BAD)-related stroke patients have the risk of early neurological deterioration (END) with disability. The efficacy and safety of intensive antiplatelet therapy using intravenous tirofiban combined with aspirin in this population remain unclear.

The stroke pre-clinical assessment network (SPAN) was created to improve the selection of putative cerebroprotectants prior to launching human clinical trials.

Ped Optimal treatment strategies for acute childhood arterial ischemic stroke are unknown, and practice is largely based on extrapolation from adult data. While thrombolysis and thrombectomy are both treatments that are commonly used to treat acute childhood arterial ischemic stroke, there are key knowledge gaps which have led to controversies regarding the optimal acute care of stroke in children. In this session, pediatric stroke experts will debate the optimal thrombolytic agent in children and neurointervention experts will debate the minimum age for which thrombectomy should be utilized.

Patients with AIS and disabling symptoms often have limited treatment options, particularly when reperfusion therapies are not feasible. LT3001 (Odatroltide), a novel molecule that enhances endogenous fibrinolysis and scavenges free radicals, was evaluated in two Phase 2 trials with distinct selection strategies